



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")

Notice of Business Update and Investor Presentation

Newcastle, UK - 15 July 2024 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, confirms that it will announce an update on the business on **Monday 29 July 2024** and the management team will make a presentation via the Investor Meet Company platform **at 10am on that day**.

Questions can be submitted pre-event via the [Investor Meet Company](#) dashboard up to the day before the meeting or at any time during the live presentation. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

Investors can sign up to Investor Meet Company for free at this [link](#).

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J. Ashman, CEO
Manprit Randhawa, CFO

Tel: +44 (0) 191 495 7325

**Cavendish Capital Markets Limited
(Nominated Adviser & Broker)**

Giles Balleny, Dan Hodkinson (Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith (Sales)

Tel: +44 (0) 20 7220 0500

Instinctif Partners (Media)

Melanie Toyne-Sewell / Jack Kincade

Tel: +44 (0) 20 7457 2020

SkinBioTherapeutics@instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGPURWMUPCURC